You’re offline. This is a read only version of the page.
EuroBiotixJames McIlroy
Clostridium difficile (C.diff) is a common hospital-acquired infection that around 15,000 people fall ill from each year in the UK. C.diff is difficult to treat using conventional medicine as relapse is common, occurring in around one in four cases. Faecal Microbiota Transplantation (FMT) is a promising alternative treatment for patients with recurrent C.diff. At the present time, FMT is not readily accessible in the United Kingdom. We are a social enterprise that aims to make FMT more accessible by providing hospitals and clinicians with screened, filtered, and frozen faecal transplant preparations ready for clinical use.
Update - James founded EnteroBiotix in 2016. Read the case study here.